TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01785524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beetroot Juice (Beet-It Stamina Shot) and Exercise Training
Description: The beverage is high in inorganic nitrate and bottled and supplied by James White Drinks. This supplement will be used in conjunction with supervised exercise training.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator Beverage (Beet-It Stamina Shot) & Exercise Training
Description: The beverage is identical in look and taste to Beet-It Stamina Shot but with active ingredient removed. It is also bottled and supplied by James White Drinks. This placebo supplement will be used in conjunction with supervised exercise training.
Study: NCT02778529

Intervention type: DEVICE
Group type: OTHER
Intervention: Bilateral assessment robots (BiAS)
Description: The BiAS are two passive desktop robots that will be used in this study to measure right and left arm kinematics for 4 different groups of patients.
Study: NCT03147105

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: arm ergometry
Description: home based arm ergometry, at least 4-5 sessions/week for 12 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: arm ergometry
Description: home based arm ergometry, at least 4-5 sessions/week for 12 weeks
Study: NCT04168749

Intervention type: COMBINATION_PRODUCT
Intervention: Numeta G13
Description: 10 days
Study: NCT02956629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir
Description: Participants take 3 tablets each containing 150 mg uprifosbuvir q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir
Description: Participants take 3 tablets each containing 150 mg uprifosbuvir q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir
Description: Participants take 3 tablets each containing 150 mg uprifosbuvir q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir
Description: Participants take 3 tablets each containing 150 mg uprifosbuvir q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir
Description: Participants take 3 tablets each containing 150 mg uprifosbuvir q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir
Description: Participants take 3 tablets each containing 150 mg uprifosbuvir q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruzasvir
Description: Participants take 3 capsules each containing 60 mg RZR q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruzasvir
Description: Participants take 3 capsules each containing 60 mg RZR q.d. by mouth.
Study: NCT03430609

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Transvaginal ultrasound for antral follicle count
Description: The participants will be subjected to transvaginal ultrasound for antral follicle count before surgery (1 month before surgery) and 1, 3 and 6 months after surgery. This test will be performed during the early proliferative stage (days 3 to 6 of the menstrual cycle); the size of the endometrioma and the ovary volume will be recorded, and functional cysts or suspected malignant cysts will be ruled out. For measurement of cysts, the average diameter of the three perpendicular ovary dimensions will be considered. For antral follicle count, the total number of follicles with diameters under 9 mm will be considered.
Study: NCT02956629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruzasvir
Description: Participants take 3 capsules each containing 60 mg RZR q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruzasvir
Description: Participants take 3 capsules each containing 60 mg RZR q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruzasvir
Description: Participants take 3 capsules each containing 60 mg RZR q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruzasvir
Description: Participants take 3 capsules each containing 60 mg RZR q.d. by mouth.
Study: NCT02956629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: RBV 200 mg capsules will be taken according to package instructions for a maximum of 16 weeks for any GT that meets virologic futility rules on uprifosbuvir + RZR alone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: RBV 200 mg capsules will be taken according to package instructions for a maximum of 16 weeks for any GT that meets virologic futility rules on uprifosbuvir + RZR alone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: RBV 200 mg capsules will be taken according to package instructions for a maximum of 16 weeks for any GT that meets virologic futility rules on uprifosbuvir + RZR alone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: RBV 200 mg capsules will be taken according to package instructions for a maximum of 16 weeks for any GT that meets virologic futility rules on uprifosbuvir + RZR alone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: RBV 200 mg capsules will be taken according to package instructions for a maximum of 16 weeks for any GT that meets virologic futility rules on uprifosbuvir + RZR alone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: RBV 200 mg capsules will be taken according to package instructions for a maximum of 16 weeks for any GT that meets virologic futility rules on uprifosbuvir + RZR alone.
Study: NCT01983800

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoflurane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol/midazolam
Study: NCT02202135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil
Description: IV ceftaroline 600mg every 8 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: IV vancomycin 15mg/kg every 12 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aztreonam
Description: IV aztreonam 1 g every 8 hours
Study: NCT02148094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: The demonstration project will use a prospective cohort design, enrolling individuals and following them up at multiple intervals over the course of 16 months. Study participants will be asked to take one tablet of Truvada daily, as HIV Pre-Exposure Prophylaxis, over this period. They will be asked to attend 7 regular visits at the project sites over the course of the project. In between visits, they will receive peer educator home visits every other day, as part of regular DMSC (Kolkata) and Ashodaya (Mysore/Mandya) outreach prevention activities. We plan to enroll 2000 female sex workers equally split between the two sites.
Study: NCT00129415

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UVA1 Irradiation
Description: The affected areas on the body will be treated with UVA1 (Sellemed UVA1 light source) for up to 5 times per week for 16 weeks. The UVA1 dose will be up to 130 J/cm2.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UVB Irradiation
Description: The affected areas on the body will be treated with UVB light for up to 5 times per week for 16 weeks. The maximum UVB dose will be 4000 mJ/cm2.
Study: NCT01083550

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision aid exposure
Description: Exposure to a computerized decision aid on adjuvant radioactive iodine treatment decision-making. The exposure is during one visit.
Study: NCT02360917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emerging from the Haze
Description: A 6 week psycho-educational class

Intervention type: OTHER
Group type: OTHER
Intervention: Emerging from the Haze
Description: A 6 week psycho-educational class
Study: NCT03888313

Intervention type: OTHER
Intervention: Pretreatment group consultation
Description: A consultation in group with several patients and one surgeon
Study: NCT03264625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (2000iu qd)
Description: Patients will receive oral Cholecalciferol (2000IU qd) apart from routine therapy for PD

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Routine therapy for PD
Description: Patients randomized to the placebo group will receive routine therapy for PD.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine therapy for PD
Description: Patients randomized to the placebo group will receive routine therapy for PD.
Study: NCT01316627

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Crooked Mirror Externalization Therapy
Description: After subjects complete the pre-treatment assessments, the study therapist will meet with participants to design their treatment program. Treatment will be conducted every day for 15 days, Monday through Friday, for 90-minute sessions. In addition, as a part of therapy, subjects will complete homework assignments daily. Intensive CBT for BDD is done in the form of Exposure and Response Prevention (ERP) with either the mirror retraining method or the crooked mirror externalization therapy. This involves prolonged and repeated exposures to images of the perceived defects, and prevention of ritualistic behavior (e.g., camouflaging with cosmetics, skin-picking, etc.).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mirror Retraining Method
Description: After subjects complete the pre-treatment assessments, the study therapist will meet with participants to design their treatment program. Treatment will be conducted every day for 15 days, Monday through Friday, for 90-minute sessions. In addition, as a part of therapy, subjects will complete homework assignments daily. Intensive CBT for BDD is done in the form of Exposure and Response Prevention (ERP) with either the mirror retraining method or the crooked mirror externalization therapy. This involves prolonged and repeated exposures to images of the perceived defects, and prevention of ritualistic behavior (e.g., camouflaging with cosmetics, skin-picking, etc.).
Study: NCT04978246

Intervention type: BEHAVIORAL
Intervention: Neuropsychometric Test
Description: Participants' global cognitive skills were measured by the Montreal Cognitive Assessment Test (MoCA), the Clock Drawing Test and memory functions, the Öktem Verbal Memory Processes Test (Ö-SBST), the attention functions by the Digit Span Forward and Digit Span Backwards Test, the executive functions by Categorical Fluency, Phonemic Fluency, the Stroop Test, Trail Making Test A and B, visuospatial skills were evaluated with the Rey-Osterrieth Complex Figure Test (ROCF), and behavioral symptoms were evaluated with the Neuropsychiatric Inventory (NPI).

Intervention type: BEHAVIORAL
Intervention: Neuropsychometric Test
Description: Participants' global cognitive skills were measured by the Montreal Cognitive Assessment Test (MoCA), the Clock Drawing Test and memory functions, the Öktem Verbal Memory Processes Test (Ö-SBST), the attention functions by the Digit Span Forward and Digit Span Backwards Test, the executive functions by Categorical Fluency, Phonemic Fluency, the Stroop Test, Trail Making Test A and B, visuospatial skills were evaluated with the Rey-Osterrieth Complex Figure Test (ROCF), and behavioral symptoms were evaluated with the Neuropsychiatric Inventory (NPI).
Study: NCT01790750

Intervention type: DEVICE
Group type: OTHER
Intervention: PES first, then FFES
Description: A 5-minute Pocket echocardiography system scan (PES) scan will be performed to detect PDA on neonates. This scan will be followed by a Full Featured Echocardiography System Scan (FFES) and scan results will be compared.
Study: NCT01263873

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mallinckrodt (ETT)
Description: 7.0 millimeter internal diameter for female 8.0 millimeter internal diameter for male

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parker Flex-Tip (ETT)
Description: 7.0 millimeter internal diameter for female 8.0 millimeter internal diameter for male
Study: NCT02097875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLZ-100
Study: NCT02461589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Administered subcutaneously ( s.c., under the skin) once daily. All subjects will follow a 4-week dose-escalation regimen except subjects who received semaglutide flexible dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Administered subcutaneously ( s.c., under the skin) once daily. All subjects will follow a 4-week dose-escalation regimen except subjects who received semaglutide flexible dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Administered subcutaneously ( s.c., under the skin) once daily. All subjects will follow a 4-week dose-escalation regimen except subjects who received semaglutide flexible dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Administered subcutaneously ( s.c., under the skin) once daily. All subjects will follow a 4-week dose-escalation regimen except subjects who received semaglutide flexible dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Administered subcutaneously ( s.c., under the skin) once daily. All subjects will follow a 4-week dose-escalation regimen except subjects who received semaglutide flexible dosing.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Description: Administered subcutaneously ( s.c., under the skin) once daily. All subjects will follow a 4-week dose-escalation regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Description: Administered subcutaneously ( s.c., under the skin) once daily. All subjects will follow a 4-week dose-escalation regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Description: Administered subcutaneously ( s.c., under the skin) once daily. All subjects will follow a 4-week dose-escalation regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Description: Administered subcutaneously ( s.c., under the skin) once daily. All subjects will follow a 4-week dose-escalation regimen.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered subcutaneously ( s.c., under the skin) once daily.
Study: NCT03690206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glepaglutide
Description: Glucagon-Like Peptide-2 (GLP-2) analog

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glepaglutide
Description: Glucagon-Like Peptide-2 (GLP-2) analog

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for glepaglutide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for glepaglutide
Study: NCT01903213

Intervention type: DRUG
Intervention: bixalomer
Description: Oral
Study: NCT02842086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF
Description: 200/25 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF
Description: 200/25 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF
Description: 200/25 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TDF
Description: 200/300 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF Placebo
Description: Tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TDF Placebo
Description: Tablet administered orally once daily
Study: NCT03688503

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: magnesium glycinate supplement
Description: magnesium glycinate (480 mg/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT03847428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab IV (intravenous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab IV (intravenous)
Study: NCT03430609

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Transvaginal ultrasound for antral follicle count
Description: The participants will be subjected to transvaginal ultrasound for antral follicle count before surgery (1 month before surgery) and 1, 3 and 6 months after surgery. This test will be performed during the early proliferative stage (days 3 to 6 of the menstrual cycle); the size of the endometrioma and the ovary volume will be recorded, and functional cysts or suspected malignant cysts will be ruled out. For measurement of cysts, the average diameter of the three perpendicular ovary dimensions will be considered. For antral follicle count, the total number of follicles with diameters under 9 mm will be considered.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic treatment for endometrioma Vicryl®
Description: Laparoscopic surgery will be performed by the same surgeon, according to the routine of the service.In all of the groups, endometrioma will be removed by means of the traction and countertraction techniques. Adhesiolysis will be performed to separate the ovary from the adjacent structures as needed. In case of cyst rupture, the contents will be aspirated, and the site where the endometrioma contents fell will be exhaustively rinsed. In the hemostasis , the investigators will perform suture with 2-0 Vicryl® in this group.
Study: NCT02461589

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered subcutaneously ( s.c., under the skin) once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered subcutaneously ( s.c., under the skin) once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered subcutaneously ( s.c., under the skin) once daily.
Study: NCT03430609

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic treatment for endometrioma Surgicel®
Description: Laparoscopic surgery will be performed by the same surgeon, according to the routine of the service.In all of the groups, endometrioma will be removed by means of the traction and countertraction techniques. Adhesiolysis will be performed to separate the ovary from the adjacent structures as needed. In case of cyst rupture, the contents will be aspirated, and the site where the endometrioma contents fell will be exhaustively rinsed. In this group, for hemostasis , the investigators will use matrix Surgicel®
Study: NCT03847428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab IV (intravenous)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline solution for Durvalumab and/or Bevacizumab masking (IV intravenous) or Dextrose for Durvalumab masking
Study: NCT04203719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK105
Description: AK105 is a humanized monoclonal antibody that specifically binds to PD-1. AK105 has a typical antibody structure and is composed of two lgG1 subtype heavy chains and two kappa subtypes light chains covalently linked by disulfide bonds.
Study: NCT03847428

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution for Durvalumab and/or Bevacizumab masking (IV intravenous) or Dextrose for Durvalumab masking
Study: NCT03244722

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Very-low energy Diet (VLED)
Description: Structured, intensive dietary intervention using liquid meal replacements aimed at providing 800 kcal/day with a weight loss goal of 15% from baseline
Study: NCT04203719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: a multi-target receptor tyrosine kinase inhibitor
Study: NCT03244722

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care (SOC)
Description: Standard consultation with registered dietitian to determine appropriate caloric deficit for a low calorie diet, education and advice to achieve weight loss in obese women. Standard of care for normal weight women

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care (SOC)
Description: Standard consultation with registered dietitian to determine appropriate caloric deficit for a low calorie diet, education and advice to achieve weight loss in obese women. Standard of care for normal weight women
Study: NCT04219956

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polyamine Deficient Diet
Description: Diet low in polyamines: the estimated calculated dose is 20 times lower that in an usual diet
Study: NCT04328311

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Watermelon Juice
Description: 500 mL watermelon juice (What a Melon), containing \~1 g of L-citrulline.

Intervention type: OTHER
Group type: OTHER
Intervention: Water
Description: 500 mL low nitrate water
Study: NCT04338581

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 714
Description: anti-IL-15 monoclonal antibody (Anti-IL-15 MAB)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for AMG 714

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nbUVB phototherapy
Description: Participants will undergo narrow band ultraviolet B (nbUVB) phototherapy if their total body Vitiligo Area Scoring Index (T-VASI) does not improve by ≥ 25% at Week 24 compared to Week 0. Phototherapy will be administered in accordance with the Vitiligo Working Group expert recommendations.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: nbUVB phototherapy
Description: Participants will undergo narrow band ultraviolet B (nbUVB) phototherapy if their total body Vitiligo Area Scoring Index (T-VASI) does not improve by ≥ 25% at Week 24 compared to Week 0. Phototherapy will be administered in accordance with the Vitiligo Working Group expert recommendations.
Study: NCT00982189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Participants randomized to take pravastatin (active) or matching placebo pill once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pravastatin
Description: Participants randomized to take pravastatin (active) or matching placebo pill once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril
Description: Participants randomized to take lisinopril (active) or matching placebo pill once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lisinopril
Description: Participants randomized to take lisinopril (active) or matching placebo pill once daily
Study: NCT03004963

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Body composition monitor
Description: Both body composition monitor (BCM) is used to evaluate the volume status of patients.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: clinical indexes
Description: The investigators evaluate the volume status of patients according to clinical indexes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: clinical indexes
Description: The investigators evaluate the volume status of patients according to clinical indexes.